Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SXC-2023 for acute nicotine withdrawal
NCT03887429Phase 2Completed
- Sponsor
- Promentis Pharmaceuticals, Inc.
- Start
- Mar 2019
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SXC-2023 in Tobacco Use Disorder (TUD) (4 arms), sponsored by Promentis Pharmaceuticals, Inc. Primary endpoints: Safety and Tolerability of SXC-2023 up to 5 days, Activity of SXC-2023 on Impulsivity, Measured Using Stop Signal Task at 5 days and 5 more. Started Mar 2019; status: completed.
02
Drugs
SXC-2023
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT03887429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03887429.